4-(4-Ethylphenyl)oxazol | 54289-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-Ethylphenyl)oxazol
• 英文别名: 4-(4-ethyl-phenyl)-oxazole；4-(4-Ethylphenyl)oxazole；4-(4-ethylphenyl)-1,3-oxazole
• CAS: 54289-72-4
• 化学式: C₁₁H₁₁NO
• 分子量: 173.214
• InChiKey: DQBWKFGHEULUPN-UHFFFAOYSA-N

物化性质

• 沸点：
  285.6±19.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  对乙基苯乙酮 、 formamide 生成 4-(4-Ethylphenyl)oxazol
  参考文献：
  名称：

  Mass-spectral investigation of 4-aryloxazoles

  摘要：

  DOI：

  10.1007/bf01175081

文献信息

• HIV protease inhibiting compounds
  申请人：DeGoey A. David

  公开号：US20050148623A1

  公开（公告）日：2005-07-07

  A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  披露了一种公式的化合物作为HIV蛋白酶抑制剂。还披露了用于抑制HIV感染的方法和组合物。
• HIV Protease Inhibiting Compounds
  申请人：DeGoey David A.

  公开号：US20100249181A1

  公开（公告）日：2010-09-30

  A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

  公开了一种化合物，其化学式为，用作HIV蛋白酶抑制剂。还公开了用于抑制HIV感染的方法和组合物。
• Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
  申请人：BIAL—R&D Investments, S.A.

  公开号：US11168087B2

  公开（公告）日：2021-11-09

  The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.

  本发明提供了取代的咪唑并[1,2-b]哒嗪化合物、取代的咪唑并[1,5-b]哒嗪化合物、相关化合物、含有此类化合物的组合物、医用试剂盒以及使用此类化合物和组合物治疗患者的内科疾病（如戈谢病、帕金森病、路易体病、痴呆症或多系统萎缩）的方法。本文所述的示例性取代咪唑并[1,2-b]哒嗪化合物包括取代咪唑并[1,2-b]哒嗪-3-甲酰胺化合物及其变体。
• SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
  申请人：Lysosomal Therapeutics Inc.

  公开号：US20170355702A1

  公开（公告）日：2017-12-14

  The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof.
• US7834043B2
  申请人：——

  公开号：US7834043B2

  公开（公告）日：2010-11-16